QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors

Journal Title: Journal of Pharmaceutical Research International - Year 2017, Vol 20, Issue 1

Abstract

Aim: This study used QSAR Pharmacophore-based virtual screening and molecular docking to identify lead compounds and determine structural requirements for breast cancer inhibitor development. CoMFA and CoMSIA modeling was employed to design more potential inhibitors. Materials and Methods: 3D-QSAR pharmacophore models were developed using HypoGen Module and validated by Fischer’s model and decoy test. The best pharmacophore model was employed to screen ZINC chemical library to obtain reasonable hits. Following ADMET filtering, 18 hits were subjected to further filter through docking. CoMFA and CoMSIA models were built by partial least squares on phenylindole-3-carbaldehydes derivatives. Results: 19 random runs from Fischer’s validation and decoy test which led to an enrichment factor of 48.23 and Guner-Henry factor of 0.774 show that the identified pharmacophore model is highly predictive. Top three hits (IC50=0.01~0.05 µM, fitness =52~62) were identified as potential inhibitory candidates from virtual screening and docking, and three new lead compounds were designed with predicted inhibiting potencies by pIC50 value of 8.55 from CoMFA and CoMSIA modeling and fitness value of ~59 from docking. Conclusion: Validation results and decoy test indicate that the developed pharmacophore model is highly predictive. Residue Sep6 and Cys 5 were observed as important active sites for ligand-protein binding. Top three hits were identified as more potential inhibitors, and the designed compounds show more inhibiting potencies. The QSAR and docking results obtained from this work should be useful in determining structural requirements for inhibitor development as well as in designing more potential inhibitors.

Authors and Affiliations

Lan Huang, Xuan R. Zhang, Pei H. Luo, Lun Yuan, Xang Z. Zhou, X. Gao, Ling S. Li

Keywords

Related Articles

Nephroprotective Effect of Phoenix reclinata Total Crude Root Extract on Tenofovir Induced Kidney Damage in Wistar Albino Rats

Tenofovir (TDF), used in combination with other antiretroviral agents, is an effective therapy for HIV infection. However, prolonged use of this drug is limited by a life threatening nephrotoxicity. Phoenix reclinata is...

New Prospective Materials for Chemoprevention: Three Phlomis

Aim: Plants are permanent sources of biologically active compounds, used by about 80% of the world population as manufactured drugs. The aims of this paper are to determine the mutagenic and antimutagenic activities of m...

Evaluation of Oral Examination of Medical Undergraduates in Pharmacology – A Conceptual Study

Aims: Oral examination has held an important place in medicine for centuries. Apart from some advantages, oral examinations are prone to many errors contributing towards threats to validity like Construct Under-represent...

Trend of HIV Seropositivity among Children at Teaching Tertiary Care Hospital in North India

Aim: The aim of this study is to ascertain the burden and trend of HIV sero-positivity among children attending ICTC in a teaching tertiary care hospital. Study Design: Retrospective study. Methodology: HIV seropositivit...

Possibilities of Developing New Formulations for Better Skin Protection from a Traditional Medicinal Plant Having Potent Practical Usage

Aims: Natural products obtained from different types of plants have made an important impact since ancient times throughout Asia. Since wood of Hesperethusa crenulata (Roxb.) Roem has been used traditionally by women in...

Download PDF file
  • EP ID EP313139
  • DOI 10.9734/JPRI/2017/37821
  • Views 95
  • Downloads 0

How To Cite

Lan Huang, Xuan R. Zhang, Pei H. Luo, Lun Yuan, Xang Z. Zhou, X. Gao, Ling S. Li (2017). QSAR Pharmacophore-based Virtual Screening, CoMFA and CoMSIA Modeling and Molecular Docking towards Identifying Lead Compounds for Breast Cancer Protease Inhibitors. Journal of Pharmaceutical Research International, 20(1), 1-10. https://europub.co.uk/articles/-A-313139